The price a patient pays for a brand-name drug at the pharmacy counter is, in most cases, a function of market exclusivity — the period during which no competing version of that drug can legally enter the market. That exclusivity is not a single thing. It is produced by an overlapping combination of patent protections and regulatory grants, each with distinct legal origins, durations, and strategic uses. Understanding how these mechanisms interact is foundational to understanding why brand-name drug prices hold at their levels for as long as they do.
Patents: The Baseline
A pharmaceutical patent, like any utility patent, runs for 20 years from the date the patent application is filed — not from the date of FDA approval. That distinction matters considerably in practice.
The development and regulatory review of a drug typically takes 10 to 15 years. By the time a drug reaches the market, a significant portion of the 20-year patent term has already elapsed. FDA data indicates that after approval, the remaining effective market life of a composition-of-matter patent — the most commercially valuable type, covering the drug’s active ingredient — is often 10 to 12 years.
Congress addressed this erosion through the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly called the Hatch-Waxman Act). That law created a Patent Term Extension (PTE) mechanism that allows manufacturers to recover up to five years of patent life lost during regulatory review, subject to a cap: the extended patent cannot run more than 14 years from FDA approval. PTEs are available once per patent.
Even accounting for PTEs, the base patent term alone does not tell the full story of how long a drug remains shielded from competition.
FDA-Granted Market Exclusivity: A Separate Layer
Parallel to — and legally distinct from — patents, the FDA grants market exclusivities as a matter of statutory policy. These exclusivities do not extend patent life. They operate independently, and they can apply even to a drug with no patents or patents that have expired.
The FDA recognizes several types of market exclusivity, each tied to different circumstances:
- New Chemical Entity (NCE) exclusivity: Five years from approval, granted to drugs containing an active moiety that has never been approved. During this period, the FDA may not accept an abbreviated new drug application (ANDA) from a generic competitor.
- Orphan Drug Exclusivity: Seven years from approval for drugs treating rare diseases (defined as affecting fewer than 200,000 Americans). It bars approval of competing drugs for the same condition.
- New Clinical Investigation exclusivity: Three years, granted when an existing drug is approved for a new indication, new formulation, or new route of administration, and new clinical trials were required for that approval.
- Pediatric exclusivity: Six months added to existing patents and exclusivities in exchange for conducting FDA-requested pediatric studies. Critically, this extension applies not just to the pediatric indication but to all existing protections on the drug.
- Biologics exclusivity: For biological products approved under the Biologics Price Competition and Innovation Act (BPCIA), 12 years of market exclusivity from the date of first licensure. Applications for biosimilars may not even be submitted to the FDA until four years after the reference product’s approval. The Pew Charitable Trusts notes that this period is substantially longer than the exclusivities granted by other high-income countries.
These exclusivities and patents can run concurrently, sequentially, or overlap in complex ways. A drug’s effective exclusivity is the product of whichever protection expires last.
Evergreening: Secondary Patents and the Extension of Exclusivity
The composition-of-matter patent on a drug’s active ingredient is typically the most legally robust protection — but it is rarely the only one. Pharmaceutical manufacturers routinely file additional patents on other aspects of the same product, including specific formulations, dosage forms, methods of administration, manufacturing processes, and particular therapeutic uses. These secondary patents have their own independent 20-year terms from filing.
Because secondary patents are often filed during or after the clinical development period — well after the original composition-of-matter application — they can have effective market lives extending long past the primary patent’s expiration. This practice of accumulating secondary patents to preserve commercial exclusivity beyond the original patent term is commonly called “evergreening.”
Research by the drugpatentwatch.com analysis team describes how the mechanism works in practice: if a new therapeutic indication is approved and that indication required new clinical data, the manufacturer earns three additional years of New Clinical Investigation exclusivity. If the indication qualifies as an orphan disease, it earns seven years. If pediatric studies were conducted at the FDA’s request, an additional six months accrues. Each of these layers compounds.
The Humira Case: A Documented Example
AbbVie’s adalimumab, marketed as Humira and used primarily for rheumatoid arthritis and other autoimmune conditions, is the most frequently cited example of what researchers call a “patent thicket” — a dense cluster of overlapping patents designed to prevent generic or biosimilar entry.
According to I-MAK’s 2025 analysis of pharmaceutical patenting practices, 311 patent applications have been filed on Humira, of which 165 were granted. Those granted patents, taken together, represent 43.3 years of patent protection — more than twice the 20-year limit the U.S. patent system was designed to provide. AbbVie leveraged this protection to delay biosimilar entry into the U.S. market by seven years compared to when competition began in Europe, while extracting settlements and royalty payments from potential competitors. The drug’s list price in the United States reached approximately $90,000 per year.
The Humira situation is not unique. I-MAK’s same analysis documents comparable patterns for other top-selling drugs:
- Keytruda (pembrolizumab): 180 patent applications filed, 78 granted, providing 37.3 years of protection — approximately two times the intended 20-year limit.
- Enbrel (etanercept): 154 applications filed, 74 granted, providing 49.7 years of protection — approximately 2.5 times the intended limit.
- Eliquis (apixaban): 43 applications filed, 22 granted, providing 34.1 years of protection — approximately 1.75 times the intended limit.
FiercePharma reported that I-MAK found AbbVie filed 247 patent applications for Humira and won patents that could have protected the medicine for up to 39 years. The company applied a similar strategy to its cancer drug Imbruvica, filing 165 patents on that product as well.
Orange Book Listing and Litigation as Delay Mechanisms
The FDA maintains what is formally known as “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly called the Orange Book. Brand-name manufacturers are required to list their patents in the Orange Book upon approval and as new relevant patents issue. When a generic manufacturer files an ANDA and certifies that it believes a listed patent is invalid or not infringed — a “Paragraph IV” certification — federal law automatically grants the brand manufacturer a 30-month stay of FDA approval, during which litigation can proceed. If multiple patents are listed, multiple 30-month stays may be triggered sequentially.
This litigation mechanism, combined with extensive patent listings, creates additional practical delays in generic entry that compound the formal exclusivity periods.
What Happens to Prices When Exclusivity Ends
The expiration of market exclusivity and relevant patents does not automatically produce lower prices — the timing and magnitude of price reductions depend on how many generic or biosimilar manufacturers enter and how quickly they capture market share. For small-molecule drugs with multiple generic entrants, price reductions can be substantial — often 80 to 90 percent below the brand price within several years of generic entry, as documented in FDA data on generic competition.
For biologics, the dynamics are different. The structural complexity of biologic drugs, the 12-year exclusivity period, the regulatory requirements for biosimilar approval, and the various manufacturer strategies to maintain market position have resulted in significantly slower price erosion after exclusivity ends. The U.S. also lags Europe in biosimilar uptake, partly because biosimilar exclusivity periods in the U.S. are longer than those in most comparable countries.
The Distinction Between Patent and Exclusivity
A common source of confusion is conflating patent protection with FDA-granted exclusivity. Patents are issued by the U.S. Patent and Trademark Office under patent law. FDA-granted exclusivities are created by statute as incentives within the drug approval framework. A drug can have FDA exclusivity but no relevant patents, or patents but no FDA exclusivity, or both — and the periods do not necessarily align. The operative question for pricing is which protection expires last, because that is when legally permissible competition can begin.
As the FDA’s own guidance explains, exclusivity is not added to patent life — the two run in parallel where they overlap, and whichever extends further governs when an ANDA or biosimilar application can be approved. The strategic management of both systems, through secondary patent filings, pediatric studies, new indication approvals, and litigation, is the mechanism by which effective market monopoly periods are extended beyond what either system, taken alone, would produce.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.